ANI Pharmaceuticals (ANIP)

[north40000]

OT: LLY may be anticipating Amarin’s entry into a much broader market at less cost to consumers, co-pay, with its already FDA-approved omega-3, 96% EPA(1 gm) capsule branded Vascepa. AMRN’s Reduce-It Phase 3 clinical trial with 8k + patients is scheduled for completion in 1st Qtr 2018 with 30+ primary and secondary indications including various CVDs and perhaps diabetes, T1 and/or T2.

I currently have had an off- label prescription for Vascepa since April 2013 with a co-pay of $9/month for 120 Vascepa capsules, or $27 for a 3-month supply. Family history of CVDs and Type-1 diabetes underlie that off- label scrip. My DES disappeared within the 1st week of taking the 4 capsules/day, each containing 1 gm of EPA, icosapent ethyl.

I have placed several links under N40k above in “my stocks” that, IMO, support why Amarin is my own 2nd largest $$$ investment, besides what V is doing for me personally in lipid panel results(and a correlation with the reduction by ~ a third the daily LLY insulin dose I had taken for some 60 years to “control” my T1D w/o more frequent and severe hypoglycemic reactions). 85% of our Amarin shares are currently profitable.